Kindred Bio and Single Cell Technology announce collaboration to develop antibodies for treatment of diseases in pets
7 October 2012
SAN FRANCISCO and SAN JOSE, California. (October 7, 2012)
Kindred Biosciences, Inc. (Kindred Bio) and Single Cell Technology, Inc. (Single Cell) announced today that they have entered into a collaboration to utilize Single Cell’s nanotechnology-based antibody identification platform to generate fully canine, feline, and equine antibodies (Canibody-FEMTO™, Felibody-FEMTO™, and Equibody-FEMTO™) for the treatment of diseases in companion animals. Single Cell has granted Kindred Bio exclusive worldwide license to Single Cell’s technology, which is capable of rapidly identifying femtomolar affinity companion animal antibodies without the need for hybridomas, caninization, felinization, or equinization.
“Drugs like Avastin®, Herceptin®, and Humira® that have revolutionized human medicine cannot, unfortunately, be administered to pets because they are highly immunogenic to non-humans. Canine, feline, and equine antibodies have been very difficult to develop with traditional techniques, but Single Cell Technology’s platform has revolutionized this field,” stated Richard Chin, M.D., Chief Executive Office of Kindred Bio. “Not only are these antibodies non-immunogenic to pets, but they are up to ten thousand times more potent than human antibodies now on the market. We believe that this partnership will lead to major advances in the treatment of cancer, immune diseases, and other significant medical conditions in dogs, cats, and horses.”
“We are very excited to partner with Kindred Bio to discover antibodies for an entirely new market,” said Chun-Nan Chen, Ph.D., Chief Executive Officer of Single Cell. “Kindred Bio is dramatically changing companion health care and we are pleased to demonstrate the value our technology can bring by finding antibodies where others cannot.”
Financial terms were not disclosed.
ABOUT KINDRED BIO
Kindred Bio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals.
ABOUT SINGLE CELL
Single Cell is pioneering a new approach to antibody discovery. Its technology is able to analyze the antibodies and mRNA from individual antibody secreting cells. Antibodies are rapidly screened against multiple molecules to measure their affinity and specificity, and mRNA from the cognate light and heavy chains are next-generation-sequenced and correctly paired. In addition to human and mouse cells, Single Cell’s technology can be applied to any host that concentrates plasma cells in lymphoid tissues. Founders Chun-Nan Chen and Jim Bowlby integrated advances in multiple disciplines, such as wafer fabrication, molecular biology, mathematical inference, nanotechnology, image processing, next generation sequencing, and bioinformatics. Single Cell’s approach substantially decreases the time and investment needed to discover high quality therapeutic and diagnostic antibodies.
Safe Harbor Statement
This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The inclusion of forward-looking statements should not be regarded as a representation that any of the company’s plans or objectives will be achieved. Forward-looking statements involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in any such forward-looking statement. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The companies undertake no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Avastin®, Lucentis®, and Herceptin® are registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark ofNovartis Corporation. Humira® is a registered trademark of Abbott Laboratories Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc.
Single Cell Technology